The influence of immunosuppressive agents on the risk of de novo Donor-Specific HLA antibody production in solid organ transplant recipients

Transplantation

Volumn 100, Issue 1, 2016, Pages 39-53

  O'Leary, Jacqueline G ^a   Samaniego, Millie ^b   Barrio, Marta Crespo ^c   Potena, Luciano ^d   Zeevi, Adriana ^e   Djamali, Arjang ^f   Cozzi, Emanuele ^g  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c HOSPITAL DEL MAR   (Spain)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; BORTEZOMIB; CALCINEURIN INHIBITOR; CYCLOSPORIN; DE NOVO DONOR SPECIFIC ANTIBODY; EVEROLIMUS; HLA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PLACEBO; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; ALLOANTIBODY; BIOLOGICAL MARKER; HLA ANTIGEN;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; DESENSITIZATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT FAILURE; GRAFT REJECTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG TRANSPLANTATION; MAINTENANCE THERAPY; MEDICATION COMPLIANCE; MONOTHERAPY; NONHUMAN; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; ADVERSE EFFECTS; ANIMAL; BLOOD; COMBINATION DRUG THERAPY; DRUG EFFECTS; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; BIOMARKERS; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; ORGAN TRANSPLANTATION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84952334199     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000869     Document Type: Review

References (161)

1. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-Allograft survival. N Engl J Med. 2013;369: 1215-1226.
2. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant. 2007;7:864-871.
3. Lee PC, Zhu L, Terasaki PI, et al. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation. 2009;88:568-574.
4. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al. Frequency and clinical implications of development of donor-specific and nondonor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol. 2005;16:2804-2812.
5. Pascual J, Samaniego MD, Torrealba JR, et al. Antibody-mediated rejection of the kidney after simultaneous pancreas-kidney transplantation. J Am Soc Nephrol. 2008;19:812-824.
6. Kaneku H, O'Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant. 2013;13:1541-1548.
7. O'Leary JG, Gebel HM, Ruiz R, et al. Class II alloantibody and mortality in simultaneous liver-kidney transplantation.AmJ Transplant. 2013;13:954-960.
8. Abu-Elmagd KM, Wu G, Costa G, et al. Preformed and de novo donor specific antibodies in visceral transplantation:long-Term outcome with special reference to the liver. Am J Transplant. 2012;12:3047-3060.
9. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant. 2011;11:312-319.
10. Ho EK, Vlad G, Vasilescu ER, et al. Pre-And posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Hum Immunol. 2011;72:5-10.
11. Snyder LD, Wang Z, Chen DF, et al. Implications for human leukocyte antigen antibodies after lung transplantation: A 10-year experience in 441 patients. Chest. 2013;144:226-233.
12. Angaswamy N, Saini D, Ramachandran S, et al. Development of antibodies to human leukocyte antigen precedes development of antibodies to major histocompatibility class I-related chain A and are significantly associated with development of chronic rejection after human lung transplantation. Hum Immunol. 2010;71:560-565.
13. Piemonti L, EverlyMJ, Maffi P, et al. Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes. 2013;62:1656-1664.
14. Safavi S, Robinson DR, Soresi S, et al. De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2014;33:1273-1281.
15. Topilsky Y, GandhiMJ, Hasin T, et al. Donor-specific antibodies to class II antigens are associated with accelerated cardiac allograft vasculopathy: A three-dimensional volumetric intravascular ultrasound study. Transplantation. 2013;95:389-396.
16. Fidler SJ, Irish AB, LimW, et al. Pre-Transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death. Transpl Immunol. 2013;28:148-153.
17. Willicombe M, Brookes P, Sergeant R, et al. De novo DQ donor-specific antibodies are associatedwith a significant risk of antibody-medicate rejection and transplant glomerulopathy. Transplantation. 2012;94:172-177.
18. Croze LE, Tetaz R, Roustit M, et al. Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies. Transpl Int. 2014;27:775-783.
19. Tagliamacco A, Cioni M, Comoli P, et al. DQ molecules are the principal stimulators of de novo donor specific antibodies in non sensitized pediatric recipients receiving a first kidney transplant. Transpl Int. 2014;27:667-673.
20. Reinsmoen NL, Lai CH, Mirocha J, et al. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome. Transplantation. 2014;97:595-601.
21. YousemSA, Zeevi A. The histopathology of lung allograft dysfunction associated with the development of donor-specific HLA alloantibodies. Am J Surg Pathol. 2012;36:987-992.
22. Dörje C, Midtvedt K, Holdaas H, et al. Early versus late acute antibodymediated rejection in renal transplant recipients. Transplantation. 2013; 96:79-84.
23. Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12:388-399.
24. Fotheringham J, Angel C, Goodwin J, et al. Natural history of proteinuria in renal transplant recipients developing de novo human leukocyte antigen antibodies. Transplantation. 2011;91:991-996.
25. Sánchez-Fructuoso AI, Santiago JL, Pérez-Flores I, et al. De novo anti-HLA antibodies in renal allograft recipients: A cross-section study. Transplant Proc. 2010;42:2874-2876.
26. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant. 2007;7:518-526.
27. Sadaka B, Alloway RR, Woodle ES. Management of antibody-mediated rejection in transplantation. Surg Clin North Am. 2013;93:1451-1466.
28. Ticehurst EH, Molina MR, Frank R, et al. Antibody-mediated rejection in heart transplant patients: long-Term follow up of patients with high levels of donor-directed anti-DQ antibodies. Clin Transpl. 2011: 409-414.
29. O'Leary JG, Demetris AJ, Friedman LS, et al. The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant. 2014;14:779-787.
30. O'Leary JG, Kaneku H, Jennings L, et al. Donor-specific alloantibodies are associated with fibrosis progression after liver-Transplantation in HCV-infected patients. Liver Transpl. 2014;20:655-663.
31. MorrellMR, Pilewski JM, Gries GJ, et al. De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis syndrome and death after lung transplantation. J Heart Lung Transplant. 2014;33: 1288-1294.
32. Lobo LJ, Aris RM, Schmitz J, et al. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant. 2013;32:70-77.
33. Tait BD, Sösal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013;95:19-47.
34. Reed EF, Rao P, Zhang Z, et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA-drilling down on key sources of variation. Am J Transplant. 2013;13:3050-3051.
35. Freitas MC, Rebellato LM, Ozawa M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation. 2013;95:1113-1119.
36. Yabu JM, Higgins JP, Chen G, et al. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation. 2011;91:342-347.
37. Friedlander R, Putheti P, Diaz E, et al. On the detection of anti-HLA antibodies using single antigen bead Luminex assay: lot-To-lot variations in MFI. Transplantation. 2013;96:e24-e26.
38. Book BK, Agarwal A, Milgrom AB, et al. New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies. Transplant Proc. 2005;37:640-642.
39. Gatault P, Jollet I, Paintaud G, et al. Very low residual concentrations of rituximab long after infusion still induce positive B-cell complementdependent cytotoxicity-crossmatch. Hum Immunol. 2013;74:1616-1618.
40. Gloor JM, Moore SB, Schneider BA, et al. The effect of antithymocyte globulin on anti-human leukocyte antigen antibody detection assays. Transplantation. 2007;84:258-264.
41. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157-1167.
42. Cooper JE, Gralla J, Cagle L, et al. Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation. 2011;91:1103-1109.
43. DeVos JM, Gaber AO, Knight RJ, et al. Donor-specific HLA-DQ antibodiesmay contribute to poor graft outcome after renal transplantation. Kidney Int. 2012;82:598-604.
44. Duquesnoy RJ, Marrari M. Detection of antibodies against HLA-C epitopes in patients with rejected kidney transplants. Transpl Immunol. 2011;24:164-171.
45. Wiebe C, Pochinco D, Blydt-Hansen TD, et al. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant. 2013;13:3114-3122.
46. Tambur AR, Rosati J, Roitberg S, et al. Epitope analysis of HLA-DQ antigens: what does the antibody see? Transplantation. 2014;98:157-166.
47. Del Bello A, Congy-Jolivet N, Muscari F, et al. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant. 2014;14:867-875.
48. Kanter Berga J, Pallardo Mateu LM, Beltran Catalan S, et al. Donorspecific HLA antibodies: risk factors and outcomes after kidney transplantation. Transplant Proc. 2011;43:2154-2156.
49. Kamar N, Del Bello A, Congy-Jolivet N, et al. Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimusbased calcineurin inhibitor-free regimen. Clin Transplant. 2013;27:455-462.
50. Sawinski D, Forde KA, Trofe-Clark J, et al. Persistent BK viremia does not increase intermediate-Term graft loss but is associated with de novo donor-specific antibodies. J Am Soc Nephrol. 2015;26:966-975.
51. Taner T, Gandhi MJ, SandersonSO, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant. 2012;12:1504-1510.
52. Pollack MS, Trimarchi HM, Riley DJ, et al. Shared cadaver donorhusband HLA class I mismatches as a risk factor for renal graft rejection in previously pregnant women. Hum Immunol. 1999;60:1150-1155.
53. Bray RA, Harris SB, Josephson CD, et al. Unappreciated risk factors for transplant patients: HLA antibodies in blood components. Hum Immunol. 2004;65:240-244.
54. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant. 2012;12:1192-1198.
55. Huang Y, Ramon D, Luan FL, et al. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation. Clin Transpl. 2012: 247-256.
56. Opelz G, Döhler B. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation. 2008;86:371-376.
57. Schmid-Mohler G, ThutMP, Wöthrich RP, et al. Non-Adherence to immunosuppressive medication in renal transplant recipients within the scope of the Integrative Model of Behavioral Prediction: A cross-sectional study. Clin Transplant. 2010;24:213-222.
58. De Geest S, Burkhalter H, Bogert L, et al. Psychosocial Interest Group; Swiss Transplant Cohort Study. Describing the evolution of medication nonadherence from pretransplant until 3 years post-Transplant and determining pretransplant medication nonadherence as risk factor for post-Transplant nonadherence to immunosuppressives: The Swiss Transplant Cohort Study. Transpl Int. 2014;27:657-666.
59. Almeshari K, Pall A, Chaballout A, et al. Targetedmonitoring of donor-specific HLA antibodies following renal transplantation. Clin Transpl. 2011: 395-400.
60. Gupta G, Abu Jawdeh BG, Racusen LC, et al. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies. Transplantation. 2014;97:1240-1246.
61. Athavale D, Worthington J, Webb NJ, et al. Pediatric kidney recipients may benefit from monitoring for donor-specific antibodies. Pediatr Transplant. 2014;18:258-265.
62. Baid S, Tolkoff-Rubin N, Saidman S, et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant. 2003;3:74-78.
63. Castillo-Rama M, Sebagh M, Sasatomi E, et al. "Plasma cell hepatitis" in liver allografts: identification and characterization of an IgG4-rich cohort. Am J Transplant. 2013;13:2966-2977.
64. Shin BH, Ge S, Mirocha J, et al. Regulation of anti-HLA antibodydependent natural killer cell activation by immunosuppressive agents. Transplantation. 2014;97:294-300.
65. Delgado JC, Fuller A, Ozawa M, et al. No occurrence of de novo HLA antibodies in patients with early corticosteroid withdrawal in a 5-year prospective randomized study. Transplantation. 2009;87:546-548.
66. Li L, Chaudhuri A, Chen A, et al. Efficacy and safety of thymoglobulin induction as an alternative approach for steroid-free maintenance immunosuppression in pediatric renal transplantation. Transplantation. 2010; 90:1516-1520.
67. Hardinger KL. Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy. 2006;26:1771-1783.
68. Kho MM, Bouvy AP, Cadogan M, et al. The effect of low and ultra-low dosages thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients. Transpl Immunol. 2012;26:186-190.
69. Knechtle SJ, Pirsch JD, H Fechner J Jr, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant. 2003;3:722-730.
70. Bloom DD, Hu H, Fechner JH, et al. T-lymphocyte alloresponses of Campath-1H-Treated kidney transplant patients. Transplantation. 2006; 81:81-87.
71. van der Windt DJ, Smetanka C, Macedo C, et al. Investigation of lymphocyte depletion and repopulation using alemtuzumab (Campath-1H) in cynomolgus monkeys. Am J Transplant. 2010;10:773-783.
72. Barnett AN, Hadjianastassiou VG, Mamode N. Rituximab in renal transplantation. Transpl Int. 2013;26:563-575.
73. JacksonAM, Kraus ES, Orandi BJ, et al. A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. Kidney Int. 2015;87:409-416.
74. van den Hoogen MW, Kamburova EG, Baas MC, et al. Rituximab as induction therapy after renal transplantation: A randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Transplant. 2015; 15:407-416.
75. Heidt S, Roelen DL, Vergunst M, et al. Bortezomib affects the function of human B cells: possible implications for desensitization protocols. Clin Transpl. 2009: 387-392.
76. Vo AA, LukovskyM, ToyodaM, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359:242-251.
77. Vo AA, Choi J, Cisneros K, et al. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation. 2014;98:312-319.
78. Heidt S, Roelen DL, Eijsink C, et al. Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol. 2010;159:199-207.
79. Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology. 2000;47:215-245.
80. Eggenhofer E, Steinmann JF, Renner P, et al. Mesenchymal stem cells together with mycophenolate mofetil inhibit antigen presenting cell and T cell infiltration into allogeneic heart grafts. Transpl Immunol. 2011;24:157-163.
81. Touzot M, Soulillou JP, Dantal J. Mechanistic target of rapamycin inhibitors in solid organ transplantation: from benchside to clinical use. Curr Opin Organ Transplant. 2012;17:626-633.
82. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31:335-340.
83. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and invivo. Transplantation. 1997;64:36-42.
84. Heidt S, Roelen DL, Eijsink C, et al. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation. 2008;86:1292-1300.
85. Kay JE, Kromwel L, Doe SE, et al. Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology. 1991;72:544-549.
86. Haneda M, Owaki M, Kuzuya T, et al. Comparative analysis of drug action on B-cell proliferation and differentiation for mycophenolic acid, everolimus, and prednisolone. Transplantation. 2014;97:405-412.
87. Aagaard-Tillery KM, Jelinek DF. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell Immunol. 1994; 156:493-507.
88. MatzM, Lehnert M, Lorkowski C, et al. Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation. Transpl Int. 2012;25:1106-1116.
89. Amet N, Gacad M, Petrosyan A, et al. In vitro effects of everolimus and intravenous immunoglobulin on cell proliferation and apoptosis induction in the mixed lymphocyte reaction. Transpl Immunol. 2010;23:170-173.
90. Rigol M, Solanes N, Sionis A, et al. Effects of cyclosporine, tacrolimus and sirolimus on vascular changes related to immune response. J Heart Lung Transplant. 2008;27:416-422.
91. San Segundo D, Fernández-Fresnedo G, Gago M, et al. Number of peripheral blood regulatory Tcells and lymphocyte activation at 3 months after conversion to mTOR inhibitor therapy. Transplant Proc. 2010;42:2871-2873.
92. Korczak-Kowalska G, Wierzbicki P, Bocian K, et al. The influence of immunosuppressive therapy on the development of CD4+CD25+ Tcells after renal transplantation. Transplant Proc. 2007;39:2721-2723.
93. Morelon E, Lefrançois N, Besson C, et al. Preferential increase inmemory and regulatory subsets during T-lymphocyte immune reconstitution after thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine. Transpl Immunol. 2010;23:53-58.
94. Ruggenenti P, Perico N, Gotti E, et al. Sirolimus versus cyclospoirne therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation. 2007;84:956-964.
95. Noris M, Casiraghi F, TodeschiniM, et al. Regulatory Tcells and Tcell depletion: role of immunosuppressive drugs. J Am Soc Nephrol. 2007;18: 1007-1018.
96. Jindra PT, Jin YP, Rozengurt E, et al. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol. 2008;180: 2357-2366.
97. Cupps TR, Edgar LC, Thomas CA, et al. Multiple mechanisms of B cell immunoregulation in man after administration of in vivo corticosteroids. J Immunol. 1984;132:170-175.
98. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. INTAC Study Group. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011; 364:1909-1919.
99. Nöel C, Abramowicz D, Durand D, et al. Daclizimab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol. 2009;20:1385-1392.
100. Brennan DC, Daller JA, Lake KD, et al. Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl JMed. 2006;355:1967-1977.
101. BrokhofMM, Sollinger HW, Hager DR, et al. Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients. Transplantation. 2014;97:612-617.
102. Todeschini M, Cortinovis M, Perico N, et al. In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-Thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development. J Immunol. 2013;191:2818-2828.
103. Tydén G, Ekberg H, Tufveson G, et al. A randomized, double-blind, placebo-controlled study of singe dose rituximab as induction in renal transplantation: A 3-year follow-up. Transplantation. 2012;94:e21-e22.
104. Ejaz NS, Shields AR, Alloway RR, et al. Randomized controlled pilot study of B cell-Targeted induction therapy in HLA sensitized kidney transplant recipients. Am J Transplant. 2013;13:3142-3154.
105. 3C Study Collaborative Group, Haynes R, Harden P, Judge P, et al. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): A randomised trial. Lancet. 2014;384:1684-1690.
106. Pascual J, Pirsch JD, Odorico JS, et al. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. Transplantation. 2009;87:125-132.
107. Cai J, Terasaki PI, Bloom DD, et al. Correlation between human leukocyte antigen antibody production and serumcreatinine in patients receiving sirolimus monotherapy after Campath-1H induction. Transplantation. 2004;78:919-924.
108. Ashimine S, Watarai Y, Yamamoto T, et al. Neither pre-Transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation. Kidney Int. 2014;85:425-430.
109. Kohei N, Hirai T, Omoto K, et al. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant. 2012;12:469-476.
110. Kubal CA, Mangus RS, Saxena R, et al. Crossmatch-positive liver transplantation in patients receiving thymoglobulin-rituximab induction. Transplantation. 2014;97:56-63.
111. Mangus RS, Fridell JA, Vianna RM, et al. Immunosuppression induction with rabbit anti-Thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-Term follow-up. Liver Transpl. 2012;18: 786-795.
112. Vianna RM, Mangus RS, Fridell JA, et al. Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation. Transplantation. 2008;85:1290-1293.
113. Clatworthy MR, Water CJ, Plotnek G, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med. 2009;360: 2683-2685.
114. Ishida H, Furusawa M, Shimizu T, et al. Influence of preoperative anti-HLA antibodies on short-And long-Term graft survival in recipients with or without rituximab treatment. Transpl Int. 2014;27:371-382.
115. Ius F, Sommer W, Tudorache I, et al. Preemptive treatment with therapeutic plasma exchange and rituximab for early donor-specific antibodies after lung transplantation. J Heart Lung Transplant. 2015;34:50-58.
116. Patel J, Everly M, Chang D, et al. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. J Heart Lung Transplant. 2011;30:1320-1326.
117. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation. 2010;89:277-284.
118. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody-And cell-mediated acute rejection. Transplantation. 2008;86:1754-1761.
119. Mulder A, Heidt S, VergunstM, et al. Proteasomeinhibition profoundly affects activated human B cells. Transplantation. 2013;95:1331-1337.
120. Nigos JG, Arora S, Nath P, et al. Treatment of antibody-mediated rejection in kidney transplant recipients: A single-center experience with a bortezomib-based regimen. Exp Clin Transplant. 2012;10:609-613.
121. Ejaz NS, Alloway RR, Halleck F, et al. Review of bortezomib treatment of antibody-mediated rejection in renal transplantation. Antioxid Redox Signal. 2014;21:2401-2418.
122. Dunn TB, Borja-Cacho D, Chinnakotla S, et al. High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection. Clin Transpl. 2011: 381-387.
123. Trivedi HL, Terasaki PI, Feroz A, et al. Clonal deletion with bortezomib followed by low or nomaintenance immunosuppression in renal allograft recipients. Transplantation. 2010;90:221-222.
124. Morrow WR, Frazier EA, Mahle WT, et al. Rapid reduction in donorspecific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation. 2012;93:319-324.
125. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-Affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5:443-453.
126. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010; 10:535-546.
127. Durrbach A, Pestana JM, Pearson T, et al. A Phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10:547-557.
128. Larsen CP, Grinyó J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation. 2010;90:1528-1535.
129. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant. 2012;12:210-217.
130. Lachmann N, Terasaki PI, Schönemann C. Donor-specific HLA antibodies in chronic renal allograft rejection: A prospective trial with a four-year follow-up. Clin Transpl. 2006: 171-199.
131. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013;95:410-417.
132. Langer RM, Hené R, Vitko S, et al. Everolimus plus early tacrolimus minimization: A phase III, randomized, open-label, multicentre trial in renal transplantation. Transpl Int. 2012;25:592-602.
133. Salvadori M, Scolari MP, Bertoni E, et al. Everolimus with very lowexposure cyclosporine a in de novo kidney transplantation: A multicenter, randomized, controlled trial. Transplantation. 2009;88:1194-1202.
134. Struijk GH, Minnee RC, Koch SD, et al. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney Int. 2010;78:934-940.
135. Rentenaar RJ, van Diepen FN, Meijer RT, et al. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo. Kidney Int. 2002;62:319-328.
136. Piazza A, Poggi E, Ozzella G, et al. Post-Transplant donor-specific antibody production and graft outcome in kidney transplantation: results of sixteen-year monitoring by flow cytometry. Clin Transpl. 2006:323-336.
137. Ruiz San Millán JC, López-Hoyos M, San Segundo D, et al. Predictive factors of allosensitization in renal transplant patients switched from calcineurin to mTOR inhibitors. Transpl Int. 2014;27:847-856.
138. Perbos E, Juinier E, Guidicelli G, et al. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors. Clin Transplant. 2014;28:1054-1060.
139. Sommerer C, Morath C, Shaier M, et al. Is there an increased risk of de novo donor specific HLA antibodies in calcineurin-inhibitor sparing immunosuppression? J Am Soc Nephrol. 2013;24(Suppl):598A.
140. Favi E, Silvestrini N, Pedroso J, et al. Extended-release tacrolimus plus everolimus vs extended-release tacrolimus plus micophenolate mofetil in primary deceased donor kidney transplant recipients: 1-year results of an open label, randomized phase 2 clinical trial. Am J Transplant. 2013;13(S5):Abstract B950.
141. Hoshino J, Kaneku H, EverlyMJ, et al.Using donor-specific antibodies to monitor the need for immunosuppression. Transplantation. 2012;93: 1173-1178.
142. McDonald-Hyman C, Turka LA, Blazar BR. Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci Transl Med. 2015;7:280rv2.
143. Dörner T, Lipsky PE. B cells: depletion or functional modulation in rheumatic diseases. Curr Opin Rheumatol. 2014;26:228-236.
144. Romano A, Conticello C, Cavalli M, et al. Salvage therapy of multiple myeloma: The new generation drugs. Biomed Res Int. 2014;2014:456037.
145. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol. 2006; 176:705-710.
146. Reddy V, Jayne D, Close D, et al. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther. 2013;15(Suppl 1):S2.
147. Mei HE, Schmidt S, Dörner T. Rationale of anti-CD19 immunotherapy: An option to target aut12oreactive plasma cells in autoimmunity. Arthritis Res Ther. 2012;14(Suppl 5):S1.
148. Daridon C, Blassfeld D, Reiter K, et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther. 2010;12:R204.
149. Sieger N, Fleischer SJ, Mei HE, et al. CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation. Arthritis Rheum. 2013;65:770-779.
150. Vincent FB, Morand EF, Schneider P, et al. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10:365-373.
151. Kwun J, Page E, Hong JJ, et al. Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model. Am J Transplant. 2015;15: 815-822.
152. Vincent FB, Saulep-Easton D, Figgett WA, et al. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013;24:203-215.
153. WeathingtonNM, Mallampalli RK. Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest. 2014;124:6-12.
154. Vij R, Siegel DS, Jagannath S, et al. An open-label, single-Arm, phase 2 study of single-Agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012;158:739-748.
155. Allegra A, Alonci A, Gerace D, et al. New orally active proteasome inhibitors in multiple myeloma. Leuk Res. 2014;38:1-9.
156. Riella LV, Liu T, Yang J, et al. Deleterious effect of CTLA4-Ig on a Tregdependent transplant model. Am J Transplant. 2012;12:846-855.
157. Klintmalm GB, Feng S, Lake JR, et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant. 2014;14:1817-1827.
158. Thompson P, Cardona K, Russell M, et al. CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am J Transplant. 2011;11:947-957.
159. Turgeon NA, Avila JG, Cano JA, et al. Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant. 2010;10:2082-2091.
160. Luo L, Li Z, WuW, et al. The effect of MICA antigens on kidney transplantation outcomes. Immunol Lett. 2013;156:54-58.
161. Jobert A, Rao N, Deayton S, et al. Angiotensin II type 1 receptor antibody precipitating acute vascular rejection in kidney transplantation. Nephrology (Carlton). 2015;20(Suppl 1):10-12.